
Regulatory
- Research & Development (R & D)
- Clinical Research
- SAS (Statistical Analysis System)
- Dossiers
- Pharmacovigilance
our documentation






about us
Setting new standards in pharmaceutical documentation excellence,

We strive to deliver the best pharmaceutical documentation experience for you.

We are committed to delivering the highest standard of pharmaceutical documentation.
Pharmacist have main role in pharmaceuticals sector
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam lobortis laoreet ante, ut rutrum felis tincidunt vel. Proin tellus magna, malesuada sit amet justo non, interdum congue tortor. Donec volutpat sollicitudin urna consequat luctus.
sales associate

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam lobortis laoreet ante, ut rutrum felis tincidunt vel. Proin tellus magna, malesuada sit amet justo non, interdum congue tortor. Donec volutpat sollicitudin urna consequat luctus.
retail specialist

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam lobortis laoreet ante, ut rutrum felis tincidunt vel. Proin tellus magna, malesuada sit amet justo non, interdum congue tortor. Donec volutpat sollicitudin urna consequat luctus.
studio executive

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam lobortis laoreet ante, ut rutrum felis tincidunt vel. Proin tellus magna, malesuada sit amet justo non, interdum congue tortor. Donec volutpat sollicitudin urna consequat luctus.
Business Analyst

news & blogs
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Proin nisi elit, consequat pharetra elementum nec, eleifend non turpis.
Learn how to identify, investigate, and manage Out-of-Trend (OOT) results in stability studies using CAPA, GMP principles, and risk-based approaches. Definition An Out-of-Trend (OOT) result in stability studies is a test result that remains within specification limits but deviates significantly from the expected historical trend or degradation pattern. OOT investigations help identify potential product quality…
Learn bracketing and matrixing in stability studies, ICH Q1D requirements, protocol design, regulatory expectations, and practical examples. Definition Bracketing and matrixing are reduced stability testing designs described in ICH Q1D that minimize the number of stability samples tested while maintaining scientific confidence in shelf-life determination. Bracketing evaluates only extreme configurations, while matrixing tests selected subsets…
Learn ICH Q1A(R2) stability guidelines, testing conditions, batch requirements, shelf-life determination, and GMP compliance for pharmaceuticals. Definition ICH Q1A(R2) is the internationally harmonized guideline that defines stability testing requirements for new drug substances and products. It establishes standard storage conditions, testing durations, and data requirements used to determine retest periods, shelf life, and storage recommendations…
Learn how to design a GMP-compliant stability study protocol with ICH guidelines, testing conditions, batch selection, and shelf-life evaluation. Definition A stability study protocol is a GMP-controlled document that defines how a drug product’s quality, safety, and efficacy are evaluated over time under specific environmental conditions to establish shelf life and storage requirements. Introduction Ensuring…
Learn the differences between accelerated vs long-term stability studies, ICH requirements, storage conditions, shelf-life determination, and GMP compliance. Definition Accelerated and long-term stability studies are pharmaceutical testing programs used to evaluate how drug substances and drug products degrade over time. Accelerated studies expose products to elevated temperature and humidity to predict stability and estimate shelf…
Learn ICH Q1A(R2) Pharmaceutical Stability study requirements, storage conditions, testing schedules, shelf-life determination, and GMP compliance. Definition Pharmaceutical stability studies are systematic tests conducted under controlled environmental conditions to evaluate how the quality, safety, and efficacy of a drug substance or drug product change over time. ICH Q1A(R2) provides globally accepted requirements for storage conditions,…
FAQ’s
Pharma Documentation Simplified.
Pharmaceutical documentation is the systematic recording of processes, procedures, tests, and controls involved in the manufacturing, quality assurance, and distribution of pharmaceutical products. It ensures product quality, safety, traceability, and regulatory compliance.
Documentation is critical to ensure:
• Compliance with regulatory requirements (GMP, DRAP, FDA, WHO, USP, BP)
• Product quality and patient safety
• Traceability and accountability
• Data integrity and audit readines
Common pharmaceutical documents include:
• Standard Operating Procedures (SOPs)
• Batch Manufacturing Records (BMR)
• Batch Packaging Records (BPR)
• Master Formula Records (MFR)
• Validation protocols and reports
• Quality control and stability reports
• Change control and deviation records
Good Documentation Practices (GDP) are guidelines that ensure documents are:
GDP helps maintain data integrity and regulatory compliance.
Accurate, clear, and legible
Written in real time
Properly signed and dated
Secure and traceable
All personnel involved in pharmaceutical operations share responsibility for accurate documentation. However, Quality Assurance (QA) is primarily responsible for document approval, control, revision, and archiving.
Common errors include:
* Incomplete or inconsistent records
* Missing signatures or dates
* Overwriting or use of correction fluid
* Backdating entries
* Illegible handwriting
Pharmaceutical documentation is governed by:
* USP, BP, and IP standards
* WHO-GMP guidelines
* FDA 21 CFR Parts 210, 211, and 11
* MHRA Act & Rules
* ICH guidelines
Documentation quality can be improved by:
* Regular staff training
* Standardized templates
* Routine audits and reviews
* Clear SOPs and GDP enforcement
* Use of digital documentation systems